Kedudukan dalam Saham
#41692
Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in... Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and infectious diseases, particularly those caused by coronaviruses. The company's pipeline features several key programs: UB-311 is a Phase 2 clinical trial candidate targeting toxic aggregated amyloid-beta proteins in the brain, aiming to treat Alzheimer's disease. UB-312, currently in Phase 1 clinical trials, is an investigational therapy designed to address Parkinson's disease and other synucleinopathies, including Lewy body dementia and multiple system atrophy, by targeting detrimental aggregated alpha-synuclein. An anti-tau product candidate is also under development for various neurodegenerative conditions, such as Alzheimer's disease. UB-313 is being developed to alleviate migraines by modulating calcitonin gene-related peptide. An anti-PCSK9 candidate aims to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events by targeting proprotein convertase subtilisin/kexin type 9 serine protease. In the infectious disease segment, UB-612 is a Phase 3 clinical-stage candidate engineered to neutralize the SARS-CoV-2 virus.
Harga Saham
$0.0001
Disegerakkan terakhir: 2026-08-11
Perubahan (1 tahun)
-99.76%
Perdagangan Vaxxinity, Inc. (VAXX)
Bilangan saham terbitan bagi Vaxxinity, Inc. (VAXX)
Bilangan saham terbitan setakat August 2026: 0
Menurut laporan kewangan terkini dan harga saham Vaxxinity, Inc., bilangan saham terbitan semasa ialah 0. Pada akhir August 2026, syarikat mempunyai 0 saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Vaxxinity, Inc. (VAXX) dari 2026 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun |
Saham Terbitan |
Ubah |
|
Tidak cukup data untuk tarikh yang disediakan. |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat |
Saham Terbitan |
Perbezaan |
Negara |
|
|
253.90M |
-
|
US
|
|
|
62.19M |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
0.00 |
-
|
BE
|
|
|
- |
-
|
KR
|
